RKI-1447 1342278-01-6 RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2.

IPI-145 1201438-56-3 Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immuno

AZ3146 1124329-14-1 AZ3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM); less potent to FAK, JNK1, JNK2, and Kit.

SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.

AVL-292 1202757-89-8 AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed.

INK-128 1224844-38-5 INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; 200-fold less potent to class I PI3K isoforms.

GSK-2636771 1372540-25-4 GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.

Molibresib 1260907-17-2 GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4).